Previous Page  7 / 30 Next Page
Information
Show Menu
Previous Page 7 / 30 Next Page
Page Background

Page 38

Notes:

Journal of Gastrointestinal & Digestive System | ISSN: 2161-069X | Volume: 8

&

&

October 29-30, 2018 | San Francisco, USA

International Conference on

Gastrointestinal Cancer and Therapeutics

4

th

World Congress on

Digestive & Metabolic Diseases

26

th

Annual Congress on

Cancer Science and Targeted Therapies

NASH: The increasing trend among the causes of liver cirrhosis

Ayfer Serin

Şişli Florence Nightingale Hospital, Liver Transplantation Unit, Turkey

W

hile the global prevalence of liver cirrhosis is not exactly known, the prevalence in the United States is found to be

in 0.15% to 0.27% of the population. Approximately 25% of the population of countries such as England, France,

Italy, Spain, and Finland is categorized as obese, and people diagnosed with type 2 diabetes and non-alcoholic fatty liver

disease (NAFLD), as well as other diseases resulting from metabolic syndrome, are increasing in frequency with time. Ten-

to-15% of NAFLD patients develop inflammation and fibrosis, which may eventually progress to cirrhosis and hepatocellular

carcinoma (HCC). Liver cirrhosis is an important cause of morbidity and mortality in the United States. The curative treatment

for liver cirrhosis is liver transplantation. Since 2004, our center has seen an increase in the proportion of non-alcoholic

steatohepatitis(NASH)-related liver cirrhosis transplant recipients compared to patients with etiological causes. This implies

an increase in the incidence of NASH and NASH-related diseases, including HCC in our population. While in 2009 NASH-

related liver cirrhosis patients comprised 4% of the total transplant recipients at our center, in 2017 this rate has risen up

to 20%. Together with this 5-fold increase, the patients with other primary etiologies of liver cirrhosis, such as hepatitis B,

C, and autoimmune hepatitis, have been found to have relatively high HOMA-IR index values, showing the presence of a

metabolic disorder in these patients. At the same time, the mean average BMI of the transplant patients has increased over the

years. Unfavorable developments in modern nutrition are thought to play a role in the impairment of normal metabolism and

deterioration of condition in such patients. Independently of the etiology, detection and prevention of underlying metabolic

disorders are important in end-stage liver cirrhosis patients.

Biography

Ayfer Serin, Internal Medicine Specialist and Gastroenterologist, has graduated from Trakya University School of Medicine in 1995. Between 1998 and 2002

she has completed the residency in gastroenterology at Dokuz Eylul University, and as a specialist gastroenterologist between 2006 and 2011 in several leading

government and university hospitals in Turkey. From 2011 and 2016 she has worked as a faculty physician at Ege University School of Medicine. In 2014, she

gained experience as an observer at Johns Hopkins University Hospital, Liver Transplantation Department. Since 2016, she has been working at Şişli Florence

Nigthingale Hospital Liver Transplantation Unit as a staff gastroenterologist and hepatologist. Her primary interests include liver diseases, viral hepatitis B and C

diseases, liver cirrhosis, liver neoplasms, NASH, liver tranplantation, living-donor evaluation, preparation, and treatment.

ayferserin@gmail.com

Ayfer Serin, J Gastrointest Dig Syst 2018, Volume 8

DOI: 10.4172/2161-069X-C8-085